Cancer Radio Luminescence Therapy
Unlocking the Potential of Photodynamic/Ultraviolet Light Therapy (PDT/UV-A)
in Deep Tumor Treatment
Confidential and Proprietary
The Team
Founders
 You-Yeon Won - Purdue Professor of Chemical Engineering
 Rachel Kim - 10+ years in Corporate Finance
Management Team
 Wade Lange - 30 yrs. experience in Healthcare (Big Pharma, CRO, Biotech Start-Up)
 Scott Clark - 3 yrs. experience in Healthcare (CRO)
50 years of cumulative experience in healthcare and business management
The Problem
 X-Ray therapy: standard treatment for
almost half of cancer patients
 Limitations:
o
o
o
o
Tissue burn, cell damage
Multiple costly hospital visits
Not for frail patients
Radio resistant tumors
Solution – The Lodos Technology
RLNPs
1) Inject RLNPs
directly into the tumor
CaWO4
UV
3) Activated RLNPs emit
UV light and destroy tumor
2) EBR (X-Ray) activates
RLNPs
Combination of X-Ray and UV light destroy Tumor Without Deep Penetration
Into Surrounding Tissue
Market & Lodos Potential
Cancer Incidence by Major Region Cancer Incidence by Tumor Type
- 5.28M New Cases 2017 - > 90% are Solid Tumors -
Addressable Patient Population
- 2.5M Patients 0
13%
Breast
1.69M
11%
US
2.61M
Japan
ESTIMATED NEW
CANCER CASES
4
5.28 M
Prostate
Colo-rectal
51%
EU
12%
Lung
Other
0.98M
2
13%
PATIENTS RECEIVING
EXTERNAL BEAM
RADIATION (EBR OR
X-RAY)
2.5 M
Source: ACS, EUCAN, Ministry of Health in Japan
Lodos Revenue Potential - If 10% of the EBR population were treated with Lodos technology, at an
average price range of $4000 -$5,000, the potential sales would be between $1.0B - $1.3B/yr.
6
Competition: Current and Future Radiation Approaches
Mechanism of Action
Current
Form
Radiation
Chemotherapy
X-rays
Future
Nanobiotix
Limitations
X-rays alone
Systemic side effects
X-rays plus chemotherapy drugs
Additive x-ray and chemo side effects
Enhances radiation within tumor
Damages healthy tissue near tumor
(Nanoparticles release free electrons when
x-ray activated)
Less effective against radio-resistant
tumors
Heavy Metal
Nanoparticles
Magnetism
Magforce
Magnetically-generated heat
(Alternating magnetic current heats
nanoparticles, killing nearby cells)
Damages healthy tissue near tumor
Business Model – Develop and Partner
IND Inflection: Preferred
Time to Partner
Development Stage
Preclinical
Phase I
Phase II
Development Cost
$3M
$11 M
Development Time
2 Years
3 Years
Phase III
Commercialization
Cost effective regulatory pathway with clear value inflection point
Marketing – Already Ahead
Limited number of radiation oncologists (~5000 each in US and Europe)
Allows for sales coverage with a small sales force
Attractive to potential partner organizations
Does not require purchase of new capital
Does not require changes to practice patterns
3-Year Milestones
Complete In-Progress Proof-of-Concept Studies (<12 months)
Clinical Protocol Development (12-18 months)
Formulation Optimization (12-18 months)
GLP/GMP Manufacturing Capability (18-24 months)
GLP/GMP Preclinical Trials (24-36 months)
IND Application for Human Clinical Testing (36 months)
Use of Funds
Patent and Licensing Upkeep (~$10K)
Laboratory Studies (~$10K)
Proof-of-Concept Completion
Formula Optimization
Development of Manufacturing Capability